{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:16:18Z","timestamp":1779358578306,"version":"3.51.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00508-019-1460-2","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T08:03:57Z","timestamp":1555056237000},"page":"124-135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Individualisierung der antihypertensiven Therapie bei Patienten mit Diabetes mellitus. Leitlinie der \u00d6sterreichischen Diabetes Gesellschaft (Update\u00a02019)","Individualising antihypertensive therapy in patients with diabetes.\u00a0A\u00a0guideline by the Austrian Diabetes Association (Update\u00a02019)"],"prefix":"10.1007","volume":"131","author":[{"given":"Guntram","family":"Schernthaner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph H.","family":"Saely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerit-Holger","family":"Schernthaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Watschinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"issue":"2","key":"1460_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jacc.2017.10.073","volume":"71","author":"P Muntner","year":"2018","unstructured":"Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT Jr, Whelton PK. Potential U.S. Population impact of\u00a0the\u00a02017 ACC\/AHA high blood pressure\u00a0guideline. J\u00a0Am Coll Cardiol. 2018;71(2):109\u201318.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1460_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMp1716193","volume":"378","author":"G Bakris","year":"2018","unstructured":"Bakris G, Sorrentino M. Redefining hypertension\u2014assessing the new blood-pressure guidelines. N\u00a0Engl J Med. 2018;378(6):497\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"1460_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jacc.2017.11.029","volume":"71","author":"FH Messerli","year":"2018","unstructured":"Messerli FH, Bangalore S. Lowering the thresholds of diseases: is anyone still healthy? J\u00a0Am Coll Cardiol. 2018;71(2):119\u201321.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1460_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00125-017-4537-3","volume":"61","author":"G Mancia","year":"2018","unstructured":"Mancia G, Grassi G. Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach. Diabetologia. 2018;61(3):517\u201325.","journal-title":"Diabetologia"},{"issue":"Suppl 2","key":"1460_CR5","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1007\/s00508-015-0924-2","volume":"128","author":"G Schernthaner","year":"2016","unstructured":"Schernthaner G, Drexel H, Rosenkranz A, Schernthaner GH, Watschinger B. Antihypertensive therapy in diabetes mellitus: Guidelines of the Austrian Diabetes Association 2016. Wien Klin Wochenschr. 2016;128(Suppl 2):S62\u2013S7.","journal-title":"Wien Klin Wochenschr"},{"issue":"Suppl 2","key":"1460_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00508-012-0270-6","volume":"124","author":"G Schernthaner","year":"2012","unstructured":"Schernthaner G, Drexel H, Rosenkranz AR, Schernthaner GH, Watschinger B, Austrian Diabetes Association. Antihypertensive therapy in diabetes mellitus\u20142012 guidelines of the Austrian Diabetes Association. Wien Klin Wochenschr. 2012;124(Suppl 2):23\u20137.","journal-title":"Wien Klin Wochenschr"},{"issue":"9841","key":"1460_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0140-6736(12)60987-8","volume":"380","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380(9841):601\u201310.","journal-title":"Lancet"},{"key":"1460_CR8","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, Brancati FL, Peters A, Wagenknecht L, Look AHEAD Rsearch Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481\u20136.","journal-title":"Diabetes Care"},{"issue":"2","key":"1460_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2337\/diacare.16.2.434","volume":"16","author":"J Stamler","year":"1993","unstructured":"Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screned in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434\u201344.","journal-title":"Diabetes Care"},{"issue":"7258","key":"1460_CR10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","volume":"321","author":"AI Adler","year":"2000","unstructured":"Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412\u20139.","journal-title":"BMJ"},{"issue":"10","key":"1460_CR11","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1681\/ASN.2004110919","volume":"16","author":"MA Pohl","year":"2005","unstructured":"Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J\u00a0Am Soc Nephrol. 2005;16(10):3027\u201337.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"1460_CR12","first-page":"1462","volume":"28","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O\u2019Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL, The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart\u00a0J. 2007;28(12):1462\u2013536.","journal-title":"Eur Heart J"},{"issue":"7","key":"1460_CR13","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.2337\/dc11-0178","volume":"34","author":"J Wang","year":"2011","unstructured":"Wang J, Geiss LS, Cheng YJ, Imperatore G, Saydah SH, James C, Gregg EW. Long-term and recent progress in blood pressure levels among U.S. adults with diagnosed diabetes, 1988\u20132008. Diabetes Care. 2011;34(7):1579\u201381. https:\/\/doi.org\/10.2337\/dc11-0178 .","journal-title":"Diabetes Care"},{"issue":"11","key":"1460_CR14","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","volume":"27","author":"G Mancia","year":"2009","unstructured":"Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Cl\u00e9ment D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A, European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a\u00a0European Society of Hypertension Task Force document. J\u00a0Hypertens. 2009;27(11):2121\u201358.","journal-title":"J Hypertens"},{"issue":"24","key":"1460_CR15","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1161\/CIRCULATIONAHA.111.033704","volume":"123","author":"PC Deedwania","year":"2011","unstructured":"Deedwania PC. Blood pressure control in diabetes mellitus: is lower always better, and how low should it go? Circulation. 2011;123(24):2776\u20138.","journal-title":"Circulation"},{"issue":"2","key":"1460_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1751-7176.2011.00570.x","volume":"14","author":"M Garcia-Touza","year":"2012","unstructured":"Garcia-Touza M, Sowers JR. Evidence-based hypertension treatment in patients with diabetes. J\u00a0Clin Hypertens. 2012;14(2):97\u2013102.","journal-title":"J Clin Hypertens"},{"issue":"2","key":"1460_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.2174\/157016112799304996","volume":"10","author":"RG Kalaitzidis","year":"2012","unstructured":"Kalaitzidis RG, Bakris GL. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol. 2012;10(2):156\u201361.","journal-title":"Curr Vasc Pharmacol"},{"issue":"17","key":"1460_CR18","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N\u00a0Engl J Med. 2010;362(17):1575\u201385.","journal-title":"N Engl J Med"},{"issue":"12","key":"1460_CR19","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2337\/dc17-1366","volume":"40","author":"LF Buckley","year":"2017","unstructured":"Buckley LF, Dixon DL, Wohlford GF 4th, Wijesinghe DS, Baker WL, Van Tassell BW. Intensive Versus Standard Blood Pressure Cntrol in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care. 2017;40(12):1733\u20138.","journal-title":"Diabetes Care"},{"issue":"6","key":"1460_CR20","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.2337\/dc17-1722","volume":"41","author":"TF Brouwer","year":"2018","unstructured":"Brouwer TF, Vehmeijer JT, Kalkman DN, Berger WR, van den Born BH, Peters RJ, Knops RE. Intensive blood pressure lowering in patients with and patients without type 2 diabetes: a pooled analysis from two randomized trials. Diabetes Care. 2018;41(6):1142\u20138.","journal-title":"Diabetes Care"},{"issue":"7","key":"1460_CR21","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00125-010-1702-3","volume":"53","author":"G Schernthaner","year":"2010","unstructured":"Schernthaner G, Barnett AH, Betteridge DJ, Carmena R, Ceriello A, Charbonnel B, Hanefeld M, Lehmann R, Malecki MT, Nesto R, Pirags V, Scheen A, Seufert J, Sjoh\u00f6lm A, Tsatsoulis A, DeFronzo R. Is the ADA\/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia. 2010;53(7):1258\u201369.","journal-title":"Diabetologia"},{"issue":"13","key":"1460_CR22","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.2018.0642","volume":"319","author":"IH Boer de","year":"2018","unstructured":"de Boer IH, Bakris G, Cannon CP. Individualizing blood pressure targets for people with diabetes and hypertension: comparing the ADA and the ACC\/AHA recommendations. JAMA. 2018;319(13):1319\u201320.","journal-title":"JAMA"},{"issue":"1","key":"1460_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jama.2010.884","volume":"304","author":"RM Cooper-DeHoff","year":"2010","unstructured":"Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304(1):61\u20138.","journal-title":"JAMA"},{"issue":"1","key":"1460_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2337\/dc10-1420","volume":"34","author":"RJ Anderson","year":"2011","unstructured":"Anderson RJ, Bahn GD, Moritz TE, Kaufman D, Abraira C, Duckworth W, VADT Study Group. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care. 2011;34(1):34\u20138.","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"1460_CR25","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.2337\/dc18-S009","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. 9. Cardiovascular disease and risk management: standards of medical care in diabetes\u20132018. Diabetes Care. 2018;41(suppl 1):S86\u2013S104.","journal-title":"Diabetes Care"},{"issue":"19","key":"1460_CR26","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2017","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, de Palma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr.. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J\u00a0Am Coll Cardiol. 2017;71(19):e127\u2013e248.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1460_CR27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cjca.2015.02.016","volume":"31","author":"SS Daskalopoulou","year":"2015","unstructured":"Daskalopoulou SS, Rabi D, Zamke KB, CHEP for the Canadian Hypertension Education Program. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2015;31(5):549\u201369.","journal-title":"Can J Cardiol"},{"key":"1460_CR28","volume-title":"Global guideline for type 2 diabetes","author":"International Diabetes Federation Clinical Guidelines Task Force.","year":"2012","unstructured":"International Diabetes Federation Clinical Guidelines Task Force.. Global guideline for type 2 diabetes. Brussels: IDF; 2012."},{"key":"1460_CR29","volume-title":"A global brief on hypertension","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. A global brief on hypertension. Geneva: WHO; 2013."},{"key":"1460_CR30","doi-asserted-by":"publisher","first-page":"d4891","DOI":"10.1136\/bmj.d4891","volume":"343","author":"T Krause","year":"2011","unstructured":"Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.","journal-title":"BMJ"},{"issue":"4","key":"1460_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2014.20","volume":"37","author":"K Shimamoto","year":"2014","unstructured":"Shimamoto K, Ando K, Fujita T, et\u00a0al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37(4):253\u2013390.","journal-title":"Hypertens Res"},{"issue":"2 Suppl","key":"1460_CR32","first-page":"6","volume":"61","author":"Association of Physicians of India","year":"2013","unstructured":"Association of Physicians of India. Indian guidelines on hypertension (IGH) \u2013 III. 2013. J\u00a0Assoc Physicians India. 2013;61(2 Suppl):6\u201336.","journal-title":"J Assoc Physicians India"},{"issue":"33","key":"1460_CR33","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, SpieringW, Agabiti Rosei E, Azizi M, BurnierM, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, SchmiederRE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u20133104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339","journal-title":"Eur Heart J"},{"issue":"5","key":"1460_CR34","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507\u201320.","journal-title":"JAMA"},{"issue":"24","key":"1460_CR35","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N\u00a0Engl J Med. 2008;358(24):2545\u201359.","journal-title":"N Engl J Med"},{"issue":"22","key":"1460_CR36","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N\u00a0Engl J Med. 2015;373(22):2103\u201316.","journal-title":"N Engl J Med"},{"issue":"6","key":"1460_CR37","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.2337\/dci17-0063","volume":"41","author":"JA Lamprea-Montealegre","year":"2018","unstructured":"Lamprea-Montealegre JA, de Boer IH. Reevaluating the evidence for blood pressure targets in type 2 diabetes. Diabetes Care. 2018;41(6):1132\u20133.","journal-title":"Diabetes Care"},{"issue":"6","key":"1460_CR38","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2337\/dc13-2334","volume":"37","author":"KL Margolis","year":"2014","unstructured":"Margolis KL, O\u2019Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH Jr, Lipkin EW, Narayan KM, Riddle MC Jr, Sood A, Goff DC Jr.. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37(6):1721\u20138.","journal-title":"Diabetes Care"},{"issue":"7","key":"1460_CR39","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S2213-8587(18)30099-8","volume":"6","author":"S Beddhu","year":"2018","unstructured":"Beddhu S, Greene T, Boucher R, Cushman WC, Wei G, Stoddard G, Ix JH, Chonchol M, Kramer H, Cheung AK, Kimmel PL, Whelton PK, Chertow GM. Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. Lancet Diabetes Endocrinol. 2018;6(7):555\u201363.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1460_CR40","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.2337\/dc17-2443","volume":"41","author":"EYF Wan","year":"2018","unstructured":"Wan EYF, Yu EYT, Chin WY, Fung CSC, Fong DYT, Choi EPH, Chan AKC, Lam CLK. Effect of achieved systolic blood pressure on cardiovascular outcomes in patients with type 2 diabetes: a population-based retrospective cohort study. Diabetes Care. 2018;41(6):1134\u201341.","journal-title":"Diabetes Care"},{"issue":"9118","key":"1460_CR41","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, Dahl\u00f6f B, Elmfeldt D, Julius S, M\u00e9nard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755\u201362.","journal-title":"Lancet"},{"issue":"7160","key":"1460_CR42","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703\u201313.","journal-title":"BMJ"},{"issue":"24","key":"1460_CR43","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1093\/eurheartj\/ehx809","volume":"39","author":"BA Bergmark","year":"2018","unstructured":"Bergmark BA, Scirica BM, Steg PG, Fanola CL, Gurmu Y, Mosenzon O, Cahn A, Raz I, Bhatt DL, SAVOR-TIMI 53 Investigators. Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. Eur Heart\u00a0J. 2018;39(24):2255\u201362.","journal-title":"Eur Heart J"},{"key":"1460_CR44","volume-title":"Type 2 diabetes. Principle and practice","author":"G Schernthaner","year":"2007","unstructured":"Schernthaner G, Schernthaner GH. Hypertension and diabetes: need for combination therapy. In: Goldstein BJ, M\u00fcller-Wieland D, Hrsg. Type 2 diabetes. Principle and practice. 2.\u00a0Aufl. New York: Informa Healthcare; 2007.","edition":"2"},{"issue":"9638","key":"1460_CR45","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Mets\u00e4rinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a\u00a0multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547\u201353.","journal-title":"Lancet"},{"issue":"1","key":"1460_CR46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jacc.2011.09.040","volume":"59","author":"J Redon","year":"2012","unstructured":"Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, B\u00f6hm M, Williams B, Yusoff K, Teo K, Yusuf S, ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J\u00a0Am Coll Cardiol. 2012;59(1):74\u201383.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1460_CR47","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/157488612800492771","volume":"7","author":"F Angeli","year":"2012","unstructured":"Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Garofoli M, Ramundo E, Biadetti A, Verdecchia P. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. Curr Drug Saf. 2012;7(1):76\u201385.","journal-title":"Curr Drug Saf"},{"issue":"Suppl","key":"1460_CR48","first-page":"337","volume":"2","author":"KDIGO Blood Pressure Work Group","year":"2012","unstructured":"KDIGO Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2012;2(Suppl):337\u2013414.","journal-title":"Kidney Int"},{"issue":"1","key":"1460_CR49","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jacc.2010.02.046","volume":"56","author":"MA Weber","year":"2010","unstructured":"Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahl\u00f6f B, Kelly RY, Hua TA, Hester A, Pitt B, ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. J\u00a0Am Coll Cardiol. 2010;56(1):77\u201385.","journal-title":"J Am Coll Cardiol"},{"key":"1460_CR50","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12933-016-0391-8","volume":"15","author":"B Bohn","year":"2016","unstructured":"Bohn B, Sch\u00f6fl C, Zimmer V, Hummel M, Heise N, Siegel E, Karges W, Riedl M, Holl RW, DPV-initiative. Achievement of treatmnt goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a\u00a0German\/Austrian DPV-multicenter analysis. Cardiovasc Diabetol. 2016;15:72.","journal-title":"Cardiovasc Diabetol"},{"key":"1460_CR51","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jcjd.2017.01.005","volume":"42","author":"J Grenier","year":"2018","unstructured":"Grenier J, Goodman SG, Leiter LA, Langer A, Teoh H, Bhatt DL, Cheng AYY, Tan MK, Ransom T, Connelly KA, Yan AT. Blood pressure management in adults with type2 diabetes: insights from the diabetes mellitus status in Canada (DM-SCAN) survey. Can J Diabetes. 2018;42:130\u20137.","journal-title":"Can J Diabetes"},{"key":"1460_CR52","first-page":"1928","volume":"8","author":"QRJ Adumaityte","year":"2006","unstructured":"Adumaityte QRJ. A meta-analysis of the effect of thiazolidinediones on blood pressure. J\u00a0Clin Hypertens. 2006;8:1928.","journal-title":"J Clin Hypertens"},{"issue":"8","key":"1460_CR53","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/dom.12085","volume":"15","author":"B Wang","year":"2013","unstructured":"Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a\u00a0meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15(8):737\u201349.","journal-title":"Diabetes Obes Metab"},{"key":"1460_CR54","doi-asserted-by":"crossref","first-page":"e005686","DOI":"10.1161\/JAHA.117.005686","volume":"6","author":"WL Baker","year":"2017","unstructured":"Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, Carbone S, Abbate Dixon DL. Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis. J\u00a0Am Heart Assoc. 2017;6:e5686.","journal-title":"J Am Heart Assoc"},{"key":"1460_CR55","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2. Diabetes. N\u00a0Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1460_CR56","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N\u00a0Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1460_CR57","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00125-018-4547-9","volume":"61","author":"G Schernthaner","year":"2018","unstructured":"Schernthaner G, Schernthaner-Reiter MH. Diabetes in the older patient: heterogeneity requires individualization of therapeutic strategies. Diabetologia. 2018;61:1503\u201316.","journal-title":"Diabetologia"},{"issue":"10","key":"1460_CR58","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJMoa1007994","volume":"364","author":"H Haller","year":"2011","unstructured":"Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N\u00a0Engl J Med. 2011;364(10):907\u201317.","journal-title":"N Engl J Med"},{"issue":"5","key":"1460_CR59","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/HJH.0000000000001276","volume":"35","author":"C Thomopoulos","year":"2017","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J\u00a0Hypertens. 2017;35(5):922\u201344.","journal-title":"J Hypertens"},{"key":"1460_CR60","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ijcard.2016.01.197","volume":"208","author":"XX Xie","year":"2016","unstructured":"Xie XX, Liu P, Wan FY, Lin SG, Zhong WL, Yuan ZK, Zou JJ, Liu LB. Blood pressure lowering and stroke events in type 2 diabetes: a network meta-analysis of randomized controlled trials. Int J Cardiol. 2016;208:141\u20136.","journal-title":"Int J Cardiol"},{"issue":"1","key":"1460_CR61","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.atherosclerosis.2008.03.002","volume":"202","author":"JA Dormandy","year":"2009","unstructured":"Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L, PROactive investigators. Impact of peripheral arterial disease in patients with diabetes\u2014results from PROactive (PROactive 11). Atherosclerosis. 2009;202(1):272\u201381.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1460_CR62","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.109.142240","volume":"55","author":"AA Bavry","year":"2010","unstructured":"Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-Dehoff RM, Handberg EM, Pepine CJ. Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the International VErapamil-SR\/Trandolapril STudy. Hypertension. 2010;55(1):48\u201353.","journal-title":"Hypertension"},{"issue":"5","key":"1460_CR63","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.117.10713","volume":"71","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Steinkamp J, Chiu N, Petrie B, Mirzan H. Intensive blood pressure targets for diabetic and other high-risk populations: a pooled individual patient data analysis. Hypertension. 2018;71(5):833\u20139.","journal-title":"Hypertension"},{"key":"1460_CR64","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1097\/HJH.0000000000001548","volume":"35","author":"C Thomopoulous","year":"2017","unstructured":"Thomopoulous C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure: overview and meta-analyses of randomized trials. J\u00a0Hypertens. 2017;35:2138\u201349.","journal-title":"J Hypertens"},{"key":"1460_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-018-0079-5","author":"E Papadopoulou","year":"2018","unstructured":"Papadopoulou E, Angeloudi E, Karras S, Sarafidis P. The optimal blood pressure target in diabetes mellitus: a\u00a0quest coming to an end? J\u00a0Hum Hypertens. 2018; https:\/\/doi.org\/10.1038\/s41371-018-0079-5 .","journal-title":"J Hum Hypertens"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-1460-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-019-1460-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-1460-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T20:49:38Z","timestamp":1663274978000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-019-1460-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":65,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1460"],"URL":"https:\/\/doi.org\/10.1007\/s00508-019-1460-2","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]},"assertion":[{"value":"12 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.H. Saely hat in Bezug auf diesen Artikel von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: MSD, Merck, AstraZeneca, Novartis, Pfizer, Genericon, Takeda, Bayer, Roche. H.\u00a0Drexel: hat in Bezug auf diesen Artikel von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amgen, AstraZeneca, Bayer Austria, Boehringer-Ingelheim, Meda Pharma, Merck Sharp & Dohme, Novo Nordisk, sanofi-aventis, Servier. G.\u00a0Schernthaner, G.-H.\u00a0Schernthaner und B.\u00a0Watschinger geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}